A detailed history of Legal & General Group PLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 4,345 shares of TSVT stock, worth $12,991. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,345
Previous 4,345 -0.0%
Holding current value
$12,991
Previous $20,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$3.6 - $5.79 $4,464 - $7,179
-1,240 Reduced 22.2%
4,345 $16,000
Q1 2024

Jul 01, 2024

BUY
$3.09 - $6.0 $3,831 - $7,440
1,240 Added 28.54%
5,585 $29,000
Q1 2024

May 14, 2024

SELL
$3.09 - $6.0 $8,704 - $16,902
-2,817 Reduced 39.33%
4,345 $23,000
Q4 2023

Feb 15, 2024

SELL
$1.57 - $4.58 $31,221 - $91,077
-19,886 Reduced 73.52%
7,162 $30,000
Q3 2023

Nov 14, 2023

SELL
$3.14 - $11.2 $41,193 - $146,932
-13,119 Reduced 32.66%
27,048 $106,000
Q2 2023

Aug 14, 2023

BUY
$8.45 - $12.48 $179,131 - $264,563
21,199 Added 111.76%
40,167 $406,000
Q1 2023

May 15, 2023

BUY
$9.21 - $14.98 $44,530 - $72,428
4,835 Added 34.21%
18,968 $193,000
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $5,493 - $10,897
641 Added 4.75%
14,133 $132,000
Q3 2022

Nov 14, 2022

SELL
$12.56 - $17.54 $117,159 - $163,613
-9,328 Reduced 40.88%
13,492 $196,000
Q2 2022

Aug 22, 2022

BUY
$10.55 - $18.81 $16,521 - $29,456
1,566 Added 7.37%
22,820 $301,000
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $32,022 - $73,319
2,744 Added 14.82%
21,254 $363,000
Q4 2021

Feb 14, 2022

BUY
$13.77 - $42.56 $254,882 - $787,785
18,510 New
18,510 $474,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $113M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.